Drug Trial Radar · NCT06808477
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
237
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Feb 28, 2027
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Bambusa TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 72 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
BBT001Drug
BBT001 will be administered
PlaceboDrug
Placebo will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events following single and multiple administration of BBT001Time frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
- Number of participants with change in serum blood parametersTime frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
- Number of participants with change in vital sign measurements following treatment administration.Time frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
- Number of participants with change in physical examination following treatment administration.Time frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
- Number of participants with change in 12-lead ECG readingsTime frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Locations
14 sites in 4 countries. Site status is shown where the registry gives one.
First OC Dermatology
Irvine, California · Recruiting
OptiSkin Medical
New York, New York · Recruiting
Equity Medical, LLC
The Bronx, New York · Recruiting
Fremantle Dermatology
Fremantle, Western Australia, Australia · Recruiting
Linear Clinical Research
Perth, Western Australia, Australia · Completed
Optimal Clinical Trials Ltd - Christchurch
Christchurch, New Zealand · Recruiting
Pacific Clinical Research Network (PCRN) Wellington
Upper Hutt, New Zealand · Recruiting
Optimal Clinical Trials Central Auckland
Grafton, Auckland, New Zealand · Recruiting
Aotearoa Clinical Trials
Otahuhu, Auckland, New Zealand · Withdrawn
Pacific Clinical Research Network (PCRN) - Auckland
Takapuna, Auckland, New Zealand · Recruiting
Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
Lodz, Poland · Recruiting
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
Rzeszów, Poland · Recruiting
Państwowy Instytut Medyczny MSWiA
Warsaw, Poland · Recruiting
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
Wroclaw, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.